ECCO 2026

Precision medicine - from a static to a dynamic system

IL-23 - is this the good-bye from systemic therapy?

Early treatment concepts with infliximab

What is the best post-operative strategy in CD?

Fistulizing disease - what can we do better?

Update on upadacitinib vs. risankizumab after anti-TNF…

IL-23: from real-world to special patient population

Exciting new data on surgery - for all patient groups?

Diet as prevention and early intervention in Crohn’s…

Evolving landscape of anti-fibrotic therapy in IBD

Stop of thiopurines in patients on subcutaneous…

What is the best treatment approach in IBD?

Molecular signature–driven therapy

Should we stop thiopurines in IBD patients who are…

Switching to subcutaneous infliximab is safe as a…

Θα πρέπει να σταματήσουμε τις θειοπουρίνες σε ασθενείς…

Was ist der beste Therapieansatz bei CED?

Molekulare Medizin als Wegweiser für…

Do we need immediate postoperative prophylaxis?

Should we prevent or treat post-operative recurrence in…

Early use of infliximab positively influences longterm…

JAK–STAT inhibition as a therapeutic approach for…

LIR!C 10 yrs FUP: Is there a benefit for surgery?

Top-down vs. step-up therapy in CD

Früher Einsatz von Infliximab verbessert das…

JAK-STAT Hemmung zur Fistel-Therapie

LIR!C — suivi 10 ans: bénéfice de la chirurgie?

Top-down vs. Step-up Therapie beim Morbus Crohn

Faut-il prévenir ou traiter la récidive postopératoire…

Long term outcomes after appendicectomy in UC (5 year…

Steroid sparing effect of filgotinib in UC

ASUC: smarter use of third-line rescue therapy

Combination therapy with tofacitinib and…

Treat-2-target strategy in UC

Strategia treat-to-target nella colite ulcerosa

Resultados a largo plazo tras apendicectomía en colitis…

Effetto steroid-sparing di filgotinib nella colite…

ASUC: Derde‑lijn­therapie slimmer inzetten

Pouchchirurgie: enkel voor expertisecentra

Obefazimod as antifibrotic agent

Long-term outcomes of IL‑23 inhibitors

Langetermijn data van IL‑23 inhibitoren

Obefazimod come agente antifibrotico

Guselkumab may improve and prevent extraintestinal…

Guselkumab – does it treat only the gut?

UPA vs RISA in Crohn’s disease – a decision dilemma

Outside the gut - efficacy uf guselkumab in…

Ustekinumab is effective and safe for paediatric…

Nicht nur im Darm – Wirksamkeit von Guselkumab bei…

Guselkumab a objawy pozajelitowe

Guselkumab può migliorare e prevenire le manifestazioni…

Το ustekinumab είναι αποτελεσματικό και ασφαλές σε…

Does colectomy reduce the risk of death in UC?

Efficacy and safety of vedolizumab + upadacitinib as…

Short term transmural healing detected by US in CD…

Early and durable response with guselkumab

Etrasimod in the milder moderate UC patients

Long-term efficacy and safety of risankizumab in UC

Vedolizumab combined with upadacitinib vs Vedolizumab…

Early symptomatic response with IL-23 blockers

Short-term effectiveness and safety of Mirikizumab in…

Histo-endoscopic outcomes of guselkumab in UC

Etrasimod efficacy in mildly-to-moderately active UC…

Efficacia e sicurezza a lungo termine di risankizumab…

Efficacia e sicurezza di vedolizumab + upadacitinib…

Efficacia di Etrasimod in pazienti affetti da colite…

Frühes symptomatisches Ansprechen unter IL-23-Blockade

Vedolizumab combinado con upadacitinib vs Vedolizumab…

Efectividad y seguridad a corto plazo de Mirikizumab en…

Valutazione a breve termine della guarigione…

B-cells step into the spotlight

The STENOVA Trial. Ontunisertib shows promising results…

AGMB-129, Ontunisertib, new MoA in patients with…

Icotrokinra and systemic inflammatory burden in UC

Appendectomy - a new therapeutic option in UC

Cytotoxic CD4+ accumulate in the UC but not CD mucosa…

Impact of icotrokinra on biomarkers in UC

Apendektomie - eine neue Therapieoption bei Colitis…

Impact de l’icotrokinra sur les biomarqueurs dans la…

תאי B במרכז העניינים

Η μελέτη STENOVA: Το ontunisertib δείχνει υποσχόμενα…

Ontunisertib – ALK5-Blockade bei fistulierendem Morbus…

L’accumulo di cellule citotossiche CD4+ caratterizza la…

Ikotrokinkra a stan zapalny w colitis ulcerosa

AI endoscopic reads in acute severe UC change the…

ADHD and autism in IBD – the same or different story?

ADHD i autyzm a IBD – czy to połączenie ma znaczenie?